Literature DB >> 8556528

Development, characterization, and biological properties of meningococcal immunotype L3,7,(8),9-specific monoclonal antibodies.

A F Verheul1, A J Kuipers, A K Braat, H A Dekker, C C Peeters, H Snippe, J T Poolman.   

Abstract

In this study, we characterize the properties of nine monoclonal antibodies (MAbs) that recognize meningococcal lipopolysaccharides (LPS). The following three specific MAbs that had not been described previously were elicited in BALB/c mice by using an immunotype L3,7,9 oligosaccharide-tetanus toxoid conjugate in combination with Quil A: 4D1-B3, 3A12-E1, and 4A8-B2. These MAbs reacted with L3,7,9 LPS on immunoblots and in the LPS enzyme-linked immunosorbent assay (ELISA) and recognised strains containing L3, L3,7, L8 (except 3A12-E1), or L9 LPS in the whole-cell ELISA. The six other MAbs have been described in previous studies (K. Saukkonen, M. Leinonen, H. Abdillahi, and J.T. Poolman, Vaccine 7:325-328, 1989; R.J.P.M. Scholten, B. Kuipers, H.A. Valkenburg, J. Danjert, W.D. Zollinger, and J.T. Poolman, J. Med. Microbiol., in press) and were obtained after immunization with outer membrane protein complexes containing LPS: MN15A11, MN15A8-1, MN15A17-1, MN11A11G, MN14F20-11, and MN14F21-11. MN15A11 was specific for L3,7,9 LPS and displayed properties similar to those of 3A12-E1. MN15A17-1, MN14F20-1, and MN11A11G were cross-reactive, and MN14F21-11 was specific for the L1,8 immunotype. Epitope specificities of MAbs reacting with L3,7,(8),9 strains were analyzed. MAbs 4D1-B3, 3A12-E1, and 4A8-B2 recognized phosphoethanolamine group-containing oligosaccharide-specific epitopes. MN15A11 and MN15A17-1 were probably directed against a conformational epitope, although for MN5A11 recognition of an unknown L3,7,9-specific epitope in the 2-keto-3-deoxyoctulosonic acid (KDO)-lipid A region cannot be excluded. MN15A8-1, a strongly cross-reactive MAb, recognized a determinant which included the KDO-lipid A region and the more terminal saccharides.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8556528      PMCID: PMC368403          DOI: 10.1128/cdli.1.6.729-736.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  35 in total

1.  Nonionic block polymer surfactants enhance the avidity of antibodies in polyclonal antisera against Streptococcus pneumoniae type 3 in normal and Xid mice.

Authors:  G J Van Dam; A F Verheul; G J Zigterman; M J De Reuver; H Snippe
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

2.  Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide.

Authors:  M Pollack; J K Chia; N L Koles; M Miller; G Guelde
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

Review 3.  Bacterial endotoxins and pathogenesis.

Authors:  D C Morrison
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

4.  The interactionof antiody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancios; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

5.  Cross-reacting serum opsonins in patients with meningococcal disease.

Authors:  H K Guttormsen; R Bjerknes; A Naess; V Lehmann; A Halstensen; S Sørnes; C O Solberg
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

6.  The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis.

Authors:  H J Jennings; K G Johnson; L Kenne
Journal:  Carbohydr Res       Date:  1983-09-16       Impact factor: 2.104

7.  Immune response of infants and children to disseminated infections with Neisseria meningitidis.

Authors:  J M Griffiss; B L Brandt; D D Broud; D K Goroff; C J Baker
Journal:  J Infect Dis       Date:  1984-07       Impact factor: 5.226

8.  Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis.

Authors:  H J Jennings; C Lugowski; F E Ashton
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

9.  Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants.

Authors:  A F Verheul; J A Van Gaans; E J Wiertz; H Snippe; J Verhoef; J T Poolman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 10.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb
View more
  3 in total

1.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

Authors:  D Martin; N Cadieux; J Hamel; B R Brodeur
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

3.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.